PubRank

Olufunmilayo I Olopade

Author PubWeight™ 281.82‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006 12.45
2 Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol 2007 10.49
3 Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010 8.93
4 Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002 8.09
5 Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 2008 7.65
6 Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006 6.86
7 Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004 5.38
8 Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006 4.09
9 Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004 3.86
10 RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 2007 3.63
11 Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet 2008 3.41
12 Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006 3.02
13 Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 2007 3.02
14 Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res 2006 2.95
15 Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 2009 2.88
16 Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012 2.85
17 Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2011 2.73
18 Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005 2.70
19 Transforming epidemiology for 21st century medicine and public health. Cancer Epidemiol Biomarkers Prev 2013 2.56
20 Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 2004 2.51
21 Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006 2.49
22 Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst 2002 2.45
23 Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 2013 2.39
24 Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers. Cancer Res 2002 2.25
25 Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat 2011 2.23
26 Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 2005 2.22
27 Hormone replacement therapy and breast cancer: heterogeneous risks by race, weight, and breast density. J Natl Cancer Inst 2013 2.21
28 Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol 2010 2.20
29 A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med 2006 2.16
30 Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment. Acad Radiol 2007 2.16
31 Treatment of cancer in sub-Saharan Africa. Lancet Oncol 2013 2.07
32 ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn 2012 1.99
33 Colorectal cancer model of health disparities: understanding mortality differences in minority populations. J Clin Oncol 2006 1.93
34 Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 2010 1.90
35 Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2010 1.90
36 Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol 2008 1.89
37 A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 2009 1.84
38 A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet 2013 1.82
39 BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet 2002 1.80
40 Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med Clin North Am 2005 1.76
41 AURKA F31I polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a consortium of investigators of modifiers of BRCA1/2 study. Cancer Epidemiol Biomarkers Prev 2007 1.75
42 Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus. PLoS Genet 2010 1.74
43 Allelic imbalance (AI) identifies novel tissue-specific cis-regulatory variation for human UGT2B15. Hum Mutat 2010 1.73
44 BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 2005 1.71
45 MYC and Breast Cancer. Genes Cancer 2010 1.66
46 Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol 2006 1.60
47 Computerized analysis of digitized mammograms of BRCA1 and BRCA2 gene mutation carriers. Radiology 2002 1.58
48 Computerized analysis of mammographic parenchymal patterns for assessing breast cancer risk: effect of ROI size and location. Med Phys 2004 1.57
49 X-ray fluorescence microscopy reveals large-scale relocalization and extracellular translocation of cellular copper during angiogenesis. Proc Natl Acad Sci U S A 2007 1.55
50 Non-contrast enhanced MRI for evaluation of breast lesions: comparison of non-contrast enhanced high spectral and spatial resolution (HiSS) images versus contrast enhanced fat-suppressed images. Acad Radiol 2011 1.49
51 MYC in breast tumor progression. Expert Rev Anticancer Ther 2008 1.49
52 Computerized texture analysis of mammographic parenchymal patterns of digitized mammograms. Acad Radiol 2005 1.49
53 MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. Nat Commun 2013 1.43
54 Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution. Clin Cancer Res 2011 1.43
55 Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med 2011 1.42
56 Power spectral analysis of mammographic parenchymal patterns for breast cancer risk assessment. J Digit Imaging 2008 1.41
57 Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis 2012 1.38
58 Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a marker? Cancer J 2010 1.32
59 Confronting genetic testing disparities: knowledge is power. JAMA 2005 1.26
60 EDD, the human orthologue of the hyperplastic discs tumour suppressor gene, is amplified and overexpressed in cancer. Oncogene 2003 1.23
61 Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat 2007 1.22
62 How often do BRCA mutation carriers tell their young children of the family's risk for cancer? A study of parental disclosure of BRCA mutations to minors and young adults. J Clin Oncol 2007 1.21
63 "Why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med 2006 1.21
64 Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Causes Control 2005 1.20
65 Racial differences in genetic factors associated with breast cancer. Cancer Metastasis Rev 2003 1.20
66 MYC is amplified in BRCA1-associated breast cancers. Clin Cancer Res 2004 1.18
67 Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat 2010 1.17
68 The role of tumor-associated macrophages in breast cancer progression (review). Int J Oncol 2013 1.16
69 Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat 2013 1.16
70 Concordance in histological and biological parameters between first and second primary breast cancers. Cancer 2010 1.15
71 Genome-wide profiles of CtBP link metabolism with genome stability and epithelial reprogramming in breast cancer. Nat Commun 2013 1.13
72 Genetic susceptibility to breast cancer. Rev Endocr Metab Disord 2007 1.13
73 Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leuk Lymphoma 2012 1.13
74 Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope 2002 1.11
75 A genome-wide association study of breast cancer in women of African ancestry. Hum Genet 2012 1.11
76 Translational integrity and continuity: personalized biomedical data integration. J Biomed Inform 2008 1.09
77 Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer 2007 1.09
78 Obesity and height in urban Nigerian women with breast cancer. Ann Epidemiol 2003 1.08
79 MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat 2012 1.07
80 The effect of varying spectral resolution on the quality of high spectral and spatial resolution magnetic resonance images of the breast. J Magn Reson Imaging 2003 1.06
81 Novel germline PALB2 truncating mutations in African American breast cancer patients. Cancer 2011 1.05
82 Fourier components of inhomogeneously broadened water resonances in breast: a new source of MRI contrast. Magn Reson Med 2004 1.05
83 Modification of BRCA1-Associated Breast and Ovarian Cancer Risk by BRCA1-Interacting Genes. Cancer Res 2011 1.05
84 High spectral and spatial resolution MRI of breast lesions: preliminary clinical experience. AJR Am J Roentgenol 2006 1.04
85 Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States. J Clin Oncol 2009 1.04
86 Genetic variation in insulin-like growth factor signaling genes and breast cancer risk among BRCA1 and BRCA2 carriers. Breast Cancer Res 2009 1.04
87 DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy. Mol Carcinog 2011 1.03
88 Regulation of Tcf7l1 DNA binding and protein stability as principal mechanisms of Wnt/β-catenin signaling. Cell Rep 2013 1.03
89 Learning of your parent's BRCA mutation during adolescence or early adulthood: a study of offspring experiences. Psychooncology 2009 1.03
90 Incoming resident interest in global health: occasional travel versus a future career abroad? J Grad Med Educ 2011 1.02
91 Relationships between computer-extracted mammographic texture pattern features and BRCA1/2 mutation status: a cross-sectional study. Breast Cancer Res 2014 1.02
92 Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res 2006 1.01
93 RASSF1A polymorphism A133S is associated with early onset breast cancer in BRCA1/2 mutation carriers. Cancer Res 2008 1.01
94 Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer 2011 1.01
95 Modification of ovarian cancer risk by BRCA1/2-interacting genes in a multicenter cohort of BRCA1/2 mutation carriers. Cancer Res 2009 1.01
96 Breast cancer and race: a rising tide does not lift all boats equally. Perspect Biol Med 2005 0.99
97 Fat suppression with spectrally selective inversion vs. high spectral and spatial resolution MRI of breast lesions: qualitative and quantitative comparisons. J Magn Reson Imaging 2006 0.99
98 High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer 2012 0.99
99 When parents disclose BRCA1/2 test results: their communication and perceptions of offspring response. Cancer 2012 0.99
100 Case-control study of body size and breast cancer risk in Nigerian women. Am J Epidemiol 2010 0.98
101 Genetic determinants of breast cancer risk: a review of current literature and issues pertaining to clinical application. Breast J 2012 0.97
102 CpG island methylation affects accessibility of the proximal BRCA1 promoter to transcription factors. Breast Cancer Res Treat 2009 0.97
103 A signature of balancing selection in the region upstream to the human UGT2B4 gene and implications for breast cancer risk. Hum Genet 2011 0.97
104 Parent opinions regarding the genetic testing of minors for BRCA1/2. J Clin Oncol 2010 0.96
105 UDP-Glucuronosyltransferase 1A1 gene polymorphisms and total bilirubin levels in an ethnically diverse cohort of women. Drug Metab Dispos 2007 0.96
106 Glucocorticoid receptor expression in breast cancer associates with older patient age. Breast Cancer Res Treat 2008 0.95
107 Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol 2008 0.95
108 Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis 2013 0.95
109 Should genetic testing for BRCA1/2 be permitted for minors? Opinions of BRCA mutation carriers and their adult offspring. Am J Med Genet C Semin Med Genet 2008 0.95
110 Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent. Hum Genet 2008 0.94
111 Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol 2012 0.94
112 Adaptive trials in the neoadjuvant setting: a model to safely tailor care while accelerating drug development. J Clin Oncol 2012 0.93
113 Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Res Treat 2010 0.93
114 Fourier component imaging of water resonance in the human breast provides markers for malignancy. Phys Med Biol 2009 0.93
115 Tumor genome analysis includes germline genome: are we ready for surprises? Int J Cancer 2014 0.93
116 Genomewide scan for loss of heterozygosity and chromosomal amplification in breast carcinoma using single-nucleotide polymorphism arrays. Cancer Genet Cytogenet 2008 0.93
117 Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and breast cancer risk in Africans. Breast Cancer Res Treat 2007 0.93
118 Direct-to-consumer marketing of genetic tests for cancer: buyer beware. J Clin Oncol 2003 0.93
119 Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2011 0.92
120 Clinical implementation of a multislice high spectral and spatial resolution-based MRI sequence to achieve unilateral full-breast coverage. Magn Reson Imaging 2009 0.92
121 Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol 2012 0.91
122 Endothelial-like properties of claudin-low breast cancer cells promote tumor vascular permeability and metastasis. Clin Exp Metastasis 2013 0.91
123 Recurrent BRCA1 and BRCA2 mutations in breast cancer patients of African ancestry. Breast Cancer Res Treat 2012 0.91
124 Genetic testing in diverse populations: are researchers doing enough to get out the correct message? JAMA 2007 0.90
125 Establishment of a standing ethics/institutional review board in a nigerian university: a blueprint for developing countries. J Empir Res Hum Res Ethics 2007 0.90
126 BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. J Natl Cancer Inst 2015 0.90
127 Computerized analysis of mammographic parenchymal patterns on a large clinical dataset of full-field digital mammograms: robustness study with two high-risk datasets. J Digit Imaging 2012 0.90
128 Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2014 0.89
129 A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012 0.89
130 Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition. Mol Oncol 2012 0.89
131 Racial and ethnic disparities in breast cancer: a multilevel perspective. Med Clin North Am 2005 0.88
132 Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat 2014 0.88
133 Expression of polycomb targets predicts breast cancer prognosis. Mol Cell Biol 2013 0.88
134 rs2981582 is associated with FGFR2 expression in normal breast. Cancer Genet Cytogenet 2010 0.88
135 Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet 2011 0.87
136 Echo-planar spectroscopic imaging (EPSI) of the water resonance structure in human breast using sensitivity encoding (SENSE). Magn Reson Med 2010 0.87
137 Neo-adjuvant capecitabine chemotherapy in women with newly diagnosed locally advanced breast cancer in a resource-poor setting (Nigeria): efficacy and safety in a phase II feasibility study. Breast J 2013 0.86
138 Differential allelic expression of c.1568C > A at UGT2B15 is due to variation in a novel cis-regulatory element in the 3'UTR. Gene 2011 0.86
139 Performance of Lynch syndrome predictive models in a multi-center US referral population. Am J Gastroenterol 2011 0.86
140 Searching for large genomic rearrangements of the BRCA1 gene in a Nigerian population. Breast Cancer Res Treat 2010 0.85
141 BRCA2 mutation and the risk of hematologic malignancy. Leuk Lymphoma 2006 0.84
142 Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. Cancer 2014 0.84
143 Body fat distribution and breast cancer risk: findings from the Nigerian breast cancer study. Cancer Causes Control 2012 0.84
144 Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. Cancer Epidemiol Biomarkers Prev 2011 0.84
145 Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2011 0.83
146 c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells. BMC Cancer 2011 0.83
147 Expression and sub-cellular localization of an epigenetic regulator, co-activator arginine methyltransferase 1 (CARM1), is associated with specific breast cancer subtypes and ethnicity. Mol Cancer 2013 0.83
148 CYP2D6 genotyping and tamoxifen: an unfinished story in the quest for personalized medicine. Semin Oncol 2011 0.83
149 Factors associated with compliance to adjuvant hormone therapy in Black and White women with breast cancer. Springerplus 2013 0.83
150 The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat 2013 0.82
151 Risk assessment and genetic testing for ovarian cancer. AJR Am J Roentgenol 2010 0.82
152 Classification of breast lesions pre-contrast injection using water resonance lineshape analysis. NMR Biomed 2012 0.82
153 MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency. Tumour Biol 2013 0.82
154 Race and subset analyses in clinical trials: time to get serious about data integration. J Natl Cancer Inst 2011 0.82
155 Evidence for an ancient BRCA1 mutation in breast cancer patients of Yoruban ancestry. Fam Cancer 2008 0.81
156 Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2014 0.81
157 Breast cancer detected on an incident (second or subsequent) round of screening MRI: MRI features of false-negative cases. AJR Am J Roentgenol 2013 0.81
158 Social barriers to diagnosis and treatment of breast cancer in patients presenting at a teaching hospital in Ibadan, Nigeria. Glob Public Health 2014 0.81
159 Lack of association between common single nucleotide polymorphisms in the TERT-CLPTM1L locus and breast cancer in women of African ancestry. Breast Cancer Res Treat 2011 0.81
160 Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry. Cancer Epidemiol Biomarkers Prev 2012 0.80
161 Resistance to trastuzumab in HER2-positive mucinous invasive ductal breast carcinoma. Clin Breast Cancer 2012 0.80
162 Correlates of depressive symptoms among women seeking cancer genetic counseling and risk assessment at a high-risk cancer clinic. J Genet Couns 2006 0.79
163 Is screening with magnetic resonance imaging in BRCA mutation carriers a safe and effective alternative to prophylactic mastectomy? J Clin Oncol 2011 0.79
164 Microsatellites in the estrogen receptor (ESR1, ESR2) and androgen receptor (AR) genes and breast cancer risk in African American and Nigerian women. PLoS One 2012 0.79
165 Clinical significance of KISS1 protein expression for brain invasion and metastasis. Cancer 2011 0.78
166 Clinical implications of ERβ methylation on sporadic breast cancers in Chinese women. Med Oncol 2011 0.77
167 Interpretation of genome-wide association study results. Oncology (Williston Park) 2010 0.77
168 Single-day FISH procedure for paraffin-embedded tissue sections using a microwave oven. Biotechniques 2005 0.77
169 Incorporating a Psychological Counselor in a Cancer Risk Assessment Program: Necessity, Acceptability, and Potential Roles. J Genet Couns 2002 0.77
170 The I1307K APC polymorphism in Ashkenazi Jews with colorectal cancer: clinical and pathologic features. Cancer Genet Cytogenet 2006 0.77
171 Family history of pancreatic cancer in a high-risk cancer clinic: implications for risk assessment. J Genet Couns 2008 0.77
172 Clinicopathological significance and prognostic value of Xeroderma pigmentosum complementary group C (XPC) expression in sporadic breast cancer patients. Med Oncol 2011 0.76
173 Risk factors for pregnancy-associated breast cancer: a report from the Nigerian Breast Cancer Study. Ann Epidemiol 2013 0.76
174 Primary structure-based function characterization of BRCT domain replicates in BRCA1. Biochem Biophys Res Commun 2006 0.76
175 Protective effect of longstanding lactation and reproductive factors: a case-control study in North Tanzania. Breast Cancer Res Treat 2012 0.76
176 Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore) 2016 0.75
177 Obituary: Janet Davison Rowley 1925-2013. Cell 2014 0.75
178 The use of allelic imbalance to ascertain cis-regulation for human UGT2B7 in vivo. Eur J Clin Pharmacol 2013 0.75
179 Hidden dangers: a cryptic exon disrupts BRCA2 mRNA. Clin Cancer Res 2012 0.75
180 Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst 2017 0.75
181 Germline mutational analysis of the C19orf62 gene in African-American women with breast cancer. Breast Cancer Res Treat 2011 0.75
182 Lack of association between common UGT2B nonsynonymous single-nucleotide polymorphisms and breast cancer in populations of African ancestry. Int J Cancer 2011 0.75
183 Towards an Oncology Database (ONCOD) Using a Warehousing Approach. AMIA Jt Summits Transl Sci Proc 2012 0.75
184 Level of awareness of mammography among women attending outpatient clinics in a teaching hospital in Ibadan, South-West Nigeria. BMC Public Health 2013 0.75
185 Estrogen deprivation therapy and colon cancer risk in breast cancer patients. Breast J 2009 0.75
186 Chromosome band 16q22-linked familial AML: exclusion of candidate genes, and possible disease risk modification by NQO1 polymorphisms. Genes Chromosomes Cancer 2004 0.75